-- FleetPartners集团（澳交所代码：FPR）周四公布，其2026财年上半年调整后每股收益为0.185澳元，高于去年同期的0.17澳元。 FactSet调查的分析师此前预期每股收益为0.17澳元。 截至3月31日的六个月，公司持续经营业务的收入为3.925亿澳元，高于去年同期的3.77亿澳元。FactSet调查的分析师此前预期为2.712亿澳元。 公司预计2026财年的运营支出将在9850万澳元至9950万澳元之间。 董事会宣布派发每股0.119澳元的中期股息，将于6月1日支付给截至5月15日登记在册的股东。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661